Cognitive Bias Modification for Interpretation (CBM-I) in People With Type 2 Diabetes and Persistent Pain
- Conditions
- Type 2 DiabetesPersistent Pain
- Registration Number
- NCT06908486
- Lead Sponsor
- University of Sydney
- Brief Summary
The goal of this clinical trial is to examine the efficacy of cognitive bias modification for interpretation (CBM-I) in people with Type 2 Diabetes and persistent pain. The main question\[s\] it aims to answer is:
Participants in the CBM-I group will complete 4 online training sessions approximately half an hour each. Each session will present participants with ambiguous scenarios which may be pain-related, however the final word of the sentence will resolve the scenario as benign (thus training participants to make benign interpretations). A measure of interpretation bias will be administered following the fourth training session, and pain severity and interference will be measured at baseline, post-training, two week follow up, and three month follow up.
We hypothesise that participants in the CBM-I group will demonstrate a greater reduction in the co-primary outcomes of pain severity and pain interference over time compared to those in the placebo control.
- Detailed Description
Pre-intervention stage We will employ a dual consent process. First, participants will complete an "expression of interest" survey which contains the eligibility survey. Given it is crucial for our study to include people with diabetes and persistent pain, we will use this eligibility survey to ensure our sample meets our eligibility criteria of being 1) are over 18 years of age; 2) have been diagnosed with type 2 diabetes; 3) have persistent pain; 4) score ≥ 3 on pain severity subscale on BPI; 5) fluent in English; 6) have access to internet and ability to use a computer over three months.
Participants deemed eligible for the study will be provided with the Participant Information Statement and consent form via Qualtrics, which will provide detailed information about the study, the nature of their participation, and their rights as participants, including the right to withdraw at any point. Participants who do not consent to participate will be redirected to the end-of-survey.
After providing consent, participants will be asked to complete the baseline questionnaires: Brief Pain Inventory (BPI), Depression, Anxiety and Stress Scale (DASS-21), 12-Item Short Form Survey (SF-12), the Worries about Recurrence or Progression Scale (WARPS) and the Treatment adherence perception (TAPQ). The rationale of these measures is that they are theoretically related to interpretation biases and are hypothesised to change following training. This is expected to take approximately 15-20 minutes of their time.
Intervention stage Immediately following completion of baseline questionaries, participants will be randomised to either the CBM-I or placebo groups automatically using a computer algorithm in Qualtrics and invited to participate in the first session (training session 1) (day 1). Neither the participants nor the researchers will be aware of which group the participant has been allocated to.
Three days after completion of the first training session (day 4), participants will be invited via email automated by Qualtrics to the next training session (training session 2). On day 7, participants will be invited to the next training session (training session 3). Each training session is expected to take 10-15 minutes.
On day 14, participants will be invited to the final training session (training session 4), which will be followed immediately by the follow-up questions (follow-up 1). Participants will therefore complete four training sessions in total over the course of 14 days.
Participants will complete the BPI questionnaire prior to each CBM-I training session. Such that, BPI is measured at baseline, prior to CBM-I training session, and at two follow-up points: 2 weeks and 3 months post-intervention.
Note that participants will be asked to complete the training within two days of being email the link. The training sessions are not mandatory, and whether the participants complete each training session they will be still sent the links for the remaining training sessions.
Post-treatment On day 14, following the final training, participants will complete a series of questionnaires: BPI, DASS-21, SF-12, WARPS, TAPQ, Ambiguous cues task, Recognition Task, Post-Intervention Questionnaire. This survey is estimated to take up to approximately 30-35 minutes (inclusive of training time).
Follow-up 1 Exactly two weeks after post-treatment (day 28), participants will be invited via email and asked to complete the follow-up questionnaires (same as baseline), and the post-intervention questionnaire. This is estimated to take 15-20 minutes.
Follow-up 2 Three months after post-treatment, participants will be invited via email and asked to complete the follow-up questionnaires (same as baseline) and the post-intervention questionnaire. This is estimated to take 15-20 minutes. As outlined in the debrief statement, if the CBM-I intervention appears to be beneficial at the conclusion of the study, we will provide access to the training for all placebo group participants.
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 319
Participants must meet all of the following criteria to be relevant for inclusion.
Over 18 years of age Have a diagnosis of Type 2 diabetes. Have persistent pain (pain present on more days than not, for 3 months or longer).
Score ≥ 3 on average pain severity on the Brief Pain Inventory (BPI). Fluent in English Have access to internet and ability to use a computer over a three month period.
Participants will be excluded where they meet any of the following criteria:
Under 18 years of age No diagnosis of Type 2 diabetes No persistent pain Not fluent in English No access to internet nor ability to use a computer.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Pain severity Baseline, post intervention (day 14), Pre intervention session 2 (day 4), pre intervention session 3 (day 7) [primary timepoint], two week follow up post intervention (day 28) [primary timepoint], three month post intervention follow up (3 months) Intensity subscale of the Brief Pain Inventory
Pain interference Baseline, post intervention (day 14), Pre intervention session 2 (day 4), pre intervention session 3 (day 7) [primary timepoint], two week follow up post intervention (day 28) [primary timepoint], three month post intervention follow up (3 months) Interference subscale of the Brief Pain Inventory
- Secondary Outcome Measures
Name Time Method Interpretation bias to pain (1) Post intervention (day 14) Bias score on the Interpretation Bias Recognition Task
Health-related quality of life Baseline, post intervention (day 14), 2 week follow up (day 28), 3 month follow up (day 104) 12 Item Short Form Health Survey score
Anxiety Baseline, post intervention (day 14), 2 week follow up (day 28), 3 month follow up (day 104) Anxiety subscale of the 21 item Depression Anxiety Stress Scales
Fear of disease progression Baseline, post intervention (day 14), 2 week follow up (day 28), 3 month follow up (day 104) Worries about Recurrence or Progression Scale score
Treatment Adherence Baseline, post intervention (day 14), 2 week follow up (day 28), 3 month follow up (day 104) Treatment Adherence Perception Questionnaire
Interpretation bias to pain (2) Post intervention (day 14) Bias score on the Ambiguous Cues task (score out of 14)
Depression Baseline, post intervention (day 14), 2 week follow up (day 28), 3 month follow up (day 104) Depression subscale of the 21 item Depression Anxiety Stress Scales
Stress Baseline, post intervention (day 14), 2 week follow up (day 28), 3 month follow up (day 104) Stress subscale of the 21 item Depression Anxiety Stress Scales
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
University of Sydney
🇦🇺Camperdown, New South Wales, Australia